Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Children's Hospital of Philadelphia
Targeting of chemokine receptors may help stop allograft rejection
January 14th, 2004
Targeting of chemokine receptors may be of greater use in stopping allograft rejection than current immunosuppressive therapy. According to a study from the United States, "immunologists have typically viewed alloreactivity schematically as a function of antigen presentation, expansion of alloreactive T and B cells within regional lymphoid tissues, and cellular infiltration and destruction of an allograft. "Actual details of the steps between immune activation and accumulation of effector cells within a graft typically have not received much attention. However, just how cells know to move to and migrate within a graft or not is proving to be of...
Source: Biotech Week (2004-01-14)
|
